Capsugel Expands User Program for Enteric Capsule Technology
Capsugel gives lead users access to intrinsically enteric capsule technology and support services.
Capsugel has announced an expansion of its lead-user customer-collaboration program for its intrinsically enteric capsule technology, which integrates enteric polymers in the capsule design, providing a fully enteric dosage form without the need to apply functional coatings, the company reports.
The programs include feasibility studies with selected customers that target oral vaccine and peptide delivery, as well as early-stage development programs for small chemical entities that could benefit from an intrinsically enteric dosage form. Under the feasibility program, lead users are granted access to the technology and associated intellectual property, as well as scientific, product development and regulatory support services.
The advantages of intrinsically enteric capsule technology include minimal excipients needed for formulation, improvement of upper gastrointestinal safety, and differentiated pharmacokinetic performance, according to Capsugel statements.
Source: Capsugel
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
